Alicja Urbaniak

Instructor

University of Arkansas for Medical Sciences

faculty

15 h-index 60 pubs 567 cited

Research Areas

Cancer Treatment and Pharmacology Synthesis and biological activity Cannabis and Cannabinoid Research Phytochemicals and Antioxidant Activities Cancer-related molecular mechanisms research Pharmacological Effects and Toxicity Studies Receptor Mechanisms and Signaling

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Alicja Urbaniak's research focuses on investigating the pharmacological activities of various compounds, particularly in the context of cancer treatment. She has studied the anti-melanoma and anti-glioblastoma potential of natural compounds, including those derived from the Turkey tail mushroom and monensin analogs. Her work also extends to modifying existing drugs, such as salinomycin analogs, to target stem-like cells in breast cancer models. Urbaniak has explored the synthesis and anticancer activity of thiocolchicine derivatives and investigated cannabinoid receptors as potential targets for drug development in Ewing sarcoma. Furthermore, her recent work has touched on enhancing cancer treatment effectiveness through stromal targeting in pancreatic cancer and understanding gene regulation in the mouse estrous cycle. She has a history of collaboration with researchers at the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications.

Metrics

h-index: 15
Publications: 60
Citations: 567

Selected Publications

Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025) DOI
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025) DOI
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025) DOI
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025) DOI
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025) DOI
Monensin and Its Analogs Offer a Multi-Targeted Approach to Enhancing Metastatic Breast Cancer Immunogenicity and Cell Death (Abstract ID: 163059) (2025) DOI
474 Repositioning monensin: Enhancing anti-cancer activity and immune modulation in breast cancer cells (2025) DOI
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024) DOI
Monensin and its derivatives increase MHC Class I and II presentations in breast cancer (2024) DOI
383 Beyond Antibiotics: Monensin and its Derivatives as Promising Anti-Breast Cancer Agents (2024) DOI
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023) DOI
Experimental pharmacology in precision medicine (2023) DOI
Musashi Exerts Control of Gonadotrope Target mRNA Translation During the Mouse Estrous Cycle (2023) DOI
Monensin and its Derivatives Exhibit Anti-Melanoma Activity In Vitro (2023) DOI
The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro (2023) DOI